C4 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
19/02/2024 14:40
* C4 Therapeutics Inc CCCC.OQ CCCC.O is expected to show
a
rise in quarterly revenue when it reports results on February
21 (estimated) for the period ending December 31 2023
* The Watertown Massachusetts-based company is expected to
report
a 11.7% increase in revenue to $3.189 million from $2.85 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for C4 Therapeutics Inc is
for a
loss of 68 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for C4
Therapeutics
Inc is $11.50, above its last closing price of $7.98.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.67 -0.66 -0.52 Beat 21.2
Jun. 30 2023 -0.69 -0.69 -0.73 Missed -6.1
Mar. 31 2023 -0.73 -0.75 -0.71 Beat 4.8
Dec. 31 2022 -0.73 -0.74 -0.77 Missed -3.5
Sep. -0.65 -0.67 -0.65 Beat 3
30 2022
Jun. 30 2022 -0.70 -0.69 -0.56 Beat 19.2
Mar. 31 2022 -0.56 -0.58 -0.65 Missed -12.3
Dec. 31 2021 -0.58 -0.58 -0.31 Beat 46.8
This summary was machine generated February 19 at 14:39 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)